Drug Details

General Information of the Drug (ID: DR5051)
Name
SP600125
Synonyms
129-56-6; 1,9-Pyrazoloanthrone; SP600125; Pyrazolanthrone; Dibenzo[cd,g]indazol-6(2H)-one; Pyrazoleanthrone; SP 600125; Anthra[1,9-cd]pyrazol-6(2H)-one; SP-600125; Anthra-1,9-pyrazol-6-none; JNK Inhibitor II; 2H-Dibenzo[cd,g]indazol-6-one; C.I. 70300; ANTHRA(1,9-cd)PYRAZOL-6(2H)-ONE; NSC 75890; UNII-1TW30Y2766; NSC-75890; CHEMBL7064; MLS002693964; 2h-dibenzo(cd,g)indazol-6-one; CHEBI:90695; 1TW30Y2766; NCGC00015958-03; SAPK Inhibitor II; 1pmv; SMR000015440; SR-01000075840; NSC75890; EINECS 204-955-6; BRN 0746890; 2zmd; Kinome_3844; Tocris-1496; BiomolKI_000068; Lopac-S-5567; BiomolKI2_000072; cid_8515; DSSTox_CID_20525; DSSTox_RID_79502; CBiol_002049; DSSTox_GSID_40525; Lopac0_000473; BMK1-G8; BSPBio_001066; ChemBiol10705 Compound 4; KBioGR_000406; KBioSS_000406; cc-622; JMC517015 Compound 2; MLS002153267; MLS006011577; SCHEMBL170980; anthra[1,9-cd]pyrazol-6-one; GTPL5273; CHEMBL1725279; DTXSID2040525; SCHEMBL15583517; BCBcMAP01_000053; BDBM16018; dibenz[cd,g]indazol-6(2h)-one; KBio2_000406; KBio2_002974; KBio2_005542; KBio3_000771; KBio3_000772; Bio1_000335; Bio1_000824; Bio1_001313; Bio2_000373; Bio2_000853; HMS1362F07; HMS1667K13; HMS1792F07; HMS1990F07; HMS2250C03; HMS3229I16; HMS3261O08; HMS3267P06; HMS3295M01; HMS3403F07; HMS3412F05; HMS3654P10; HMS3676F05; HMS3747M19; ALBB-024051; AMY31086; Anthra[1,9cd]pyrazol-6(2H)-one; BCP05457; EX-A1998; Tox21_110267; Tox21_500473; Anthra[1-9-cd]pyrazol-6(2H)-one; ANW-68872; BDBM50024294; BDBM50433916; CCG-47500; Dibenzo[cd,g]indazol-6(2H)-one #; HSCI1_000136; MFCD00022289; NSC755773; s1460; SBB000595; ZINC96298875; AKOS000115584; Anthra[1,9-cd]pyrazol-6(2H)-one;; Anthrapyrazolone; 1,9-Pyrazoloanthrone; CCG-100672; CS-0196; DB01782; LP00473; MCULE-7820194475; NSC-755773; SDCCGSBI-0050458.P003; VA10299; 1,6-dihydrodibenzo[cd,g]indazol-6-one; 2,6-dihydrodibenzo[cd,g]indazol-6-one; IDI1_002128; QTL1_000077; SMP2_000240; NCGC00015958-01; NCGC00015958-02; NCGC00015958-04; NCGC00015958-05; NCGC00015958-06; NCGC00015958-07; NCGC00015958-08; NCGC00015958-22; NCGC00025186-01; NCGC00025186-02; NCGC00025186-03; NCGC00025186-04; NCGC00025186-05; NCGC00261158-01; WLN: T C6665 1A P IV OMNJ; 14,15-diazatetracyclo[7.6.1.0^{2,7}.0^{13,16}]hexadeca-1(15),2(7),3,5,9,11,13(16)-heptaen-8-one; AC-32051; AK-57219; AS-14374; CAS-129-56-6; HY-12041; JNK Inhibitor II - CAS 129-56-6; K914; SMR002530644; ST018684; DB-041928; EU-0100473; FT-0607068; SW218106-2; EN300-02083; Anthra[1,9-cd]pyrazol-6(2H)-one & Z-100; K00068; S 5567; SP600125, >=98% (HPLC); AB00075935-01; SP 600125 & Z-100; 129S566; Q4545713; SR-01000075840-1; SR-01000075840-2; SR-01000075840-4; SR-01000075840-6; SR-01000637108-1; W-108360; BRD-K01567962-001-04-0; BRD-K01567962-001-06-5; BRD-K01567962-001-08-1; BRD-K01567962-001-22-2; Z56785477; F1414-1245; 120093-15-4; 14,15-diazatetracyclo[7.6.1.0;{2,7}.0;{13,16}]hexadeca-1(15),2(7),3,5,9(16),10,12-heptaen-8-one
    Click to Show/Hide
Molecular Type
Small molecule
Disease Chronic kidney disease [ICD-11: GB61] Investigative [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C14H8N2O
PubChem CID
8515
Canonical SMILES
C1=CC=C2C(=C1)C3=NNC4=CC=CC(=C43)C2=O
InChI
1S/C14H8N2O/c17-14-9-5-2-1-4-8(9)13-12-10(14)6-3-7-11(12)15-16-13/h1-7H,(H,15,16)
InChIKey
ACPOUJIDANTYHO-UHFFFAOYSA-N
CAS Number
CAS 129-56-6
ChEBI ID
CHEBI:90695
TTD Drug ID
D02PVB
DrugBank ID
DB01782
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Saikosaponin D      Bupleurum scorzonerifolium     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Phosphorylation AKT1  Molecule Info 
Pathway MAP
Up-regulation Expression BAX  Molecule Info 
Pathway MAP
Down-regulation Expression BCL-2  Molecule Info 
Pathway MAP
Up-regulation Expression CASP3  Molecule Info 
Pathway MAP
                    In-vitro Model U2OS CVCL_0042 Osteosarcoma Homo sapiens
                    Experimental
                    Result(s)		 A dramatic inhibition of cellular proliferation, invasion, and migration in cells treated with Ssd alone or in combination with SP600125 was observed.
Target and Pathway
Target(s) Jun N terminal kinase (JNK)  Molecule Info  [3]
Tyrosine threonine kinase (MPS1)  Molecule Info  [4]
KEGG Pathway Cell cycle Click to Show/Hide
NetPath Pathway IL2 Signaling Pathway Click to Show/Hide
WikiPathways Retinoblastoma (RB) in Cancer Click to Show/Hide
References
Reference 1 SP600125 suppresses Keap1 expression and results in NRF2-mediated prevention of diabetic nephropathy. J Mol Endocrinol. 2018 Feb;60(2):145-157.
Reference 2 Use of Saikosaponin D and JNK inhibitor SP600125, alone or in combination, inhibits malignant properties of human osteosarcoma U2 cells. Am J Transl Res. 2019 Apr 15;11(4):2070-2080.
Reference 3 c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest. 2001 Jul;108(1):73-81.
Reference 4 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link